BME:ROVI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Laboratorios Farmaceuticos Rovi

Executive Summary

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. More Details


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

Share Price & News

How has Laboratorios Farmaceuticos Rovi's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ROVI has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.9%

ROVI

-3.0%

ES Pharmaceuticals

0.6%

ES Market


1 Year Return

48.1%

ROVI

-0.8%

ES Pharmaceuticals

-22.3%

ES Market

Return vs Industry: ROVI exceeded the Spanish Pharmaceuticals industry which returned -0.8% over the past year.

Return vs Market: ROVI exceeded the Spanish Market which returned -22.3% over the past year.


Shareholder returns

ROVIIndustryMarket
7 Day-1.9%-3.0%0.6%
30 Day-0.6%-5.8%3.6%
90 Day1.6%-5.2%-1.4%
1 Year48.1%48.1%2.4%-0.8%-20.0%-22.3%
3 Year96.0%94.1%22.9%8.8%-19.7%-26.9%
5 Year133.5%127.3%23.0%1.8%-16.1%-28.9%

Price Volatility Vs. Market

How volatile is Laboratorios Farmaceuticos Rovi's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Laboratorios Farmaceuticos Rovi undervalued compared to its fair value and its price relative to the market?

32.59x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ROVI (€31.1) is trading above our estimate of fair value (€29.2)

Significantly Below Fair Value: ROVI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ROVI is poor value based on its PE Ratio (32.6x) compared to the XE Pharmaceuticals industry average (21.7x).

PE vs Market: ROVI is poor value based on its PE Ratio (32.6x) compared to the Spanish market (18.8x).


Price to Earnings Growth Ratio

PEG Ratio: ROVI is poor value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: ROVI is overvalued based on its PB Ratio (4.9x) compared to the XE Pharmaceuticals industry average (3.6x).


Next Steps

Future Growth

How is Laboratorios Farmaceuticos Rovi forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

31.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ROVI's forecast earnings growth (31.1% per year) is above the savings rate (1.3%).

Earnings vs Market: ROVI's earnings (31.1% per year) are forecast to grow slower than the Spanish market (31.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ROVI's revenue (13.9% per year) is forecast to grow faster than the Spanish market (6.5% per year).

High Growth Revenue: ROVI's revenue (13.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ROVI's Return on Equity is forecast to be high in 3 years time (20.9%)


Next Steps

Past Performance

How has Laboratorios Farmaceuticos Rovi performed over the past 5 years?

13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ROVI has a high level of non-cash earnings.

Growing Profit Margin: ROVI's current net profit margins (13.3%) are higher than last year (7.9%).


Past Earnings Growth Analysis

Earnings Trend: ROVI's earnings have grown by 13.5% per year over the past 5 years.

Accelerating Growth: ROVI's earnings growth over the past year (98.3%) exceeds its 5-year average (13.5% per year).

Earnings vs Industry: ROVI earnings growth over the past year (98.3%) exceeded the Pharmaceuticals industry 13.2%.


Return on Equity

High ROE: ROVI's Return on Equity (15%) is considered low.


Next Steps

Financial Health

How is Laboratorios Farmaceuticos Rovi's financial position?


Financial Position Analysis

Short Term Liabilities: ROVI's short term assets (€351.5M) exceed its short term liabilities (€111.6M).

Long Term Liabilities: ROVI's short term assets (€351.5M) exceed its long term liabilities (€80.0M).


Debt to Equity History and Analysis

Debt Level: ROVI's debt to equity ratio (15%) is considered satisfactory.

Reducing Debt: ROVI's debt to equity ratio has reduced from 22.1% to 15% over the past 5 years.

Debt Coverage: ROVI's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: ROVI's interest payments on its debt are well covered by EBIT (59.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Laboratorios Farmaceuticos Rovi current dividend yield, its reliability and sustainability?

0.56%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: ROVI's dividend (0.56%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (2.33%).

High Dividend: ROVI's dividend (0.56%) is low compared to the top 25% of dividend payers in the Spanish market (6.74%).


Stability and Growth of Payments

Stable Dividend: ROVI is not paying a notable dividend for the Spanish market, therefore no need to check if payments are stable.

Growing Dividend: ROVI is not paying a notable dividend for the Spanish market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: ROVI is not paying a notable dividend for the Spanish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ROVI's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.1yrs

Average management tenure


CEO

Juan López-Belmonte Encina

3.75yrs

Tenure

€541,000

Compensation

Mr. Juan López-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007. Mr. Encina has been with Laboratorios Farmaceuticos ROVI since 1994 and served a ...


CEO Compensation Analysis

Compensation vs Market: Juan's total compensation ($USD640.39K) is below average for companies of similar size in the Spanish market ($USD1.22M).

Compensation vs Earnings: Juan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Juan López-Belmonte Encina
CEO & Director3.75yrs€541.00kno data
Iván López-Belmonte Encina
First Deputy Chairman & Head of Corporate Development4.92yrs€416.00kno data
Javier López-Belmonte Encina
Second Deputy Chairman & CFO4.92yrs€417.00kno data
Mercedes Benítez del Castillo Sánchez
Legal Department Managerno datano datano data
Fernando Martínez Morales
Director of Sales11.08yrsno datano data
Rosario Perucha Pérez
Marketing Managerno datano datano data
Francisco Javier Angulo García
Human Resources Managerno datano datano data
Gabriel Núñez Fernández
Secretaryno datano datano data
Ignacio Zarzalejos Toledano
Deputy Secretary2.75yrsno datano data

11.1yrs

Average Tenure

Experienced Management: ROVI's management team is seasoned and experienced (11.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Juan López-Belmonte Encina
CEO & Director3.75yrs€541.00kno data
Iván López-Belmonte Encina
First Deputy Chairman & Head of Corporate Development4.92yrs€416.00kno data
Javier López-Belmonte Encina
Second Deputy Chairman & CFO4.92yrs€417.00kno data
Juan López-Belmonte López
Chairmanno data€150.00kno data
José Fernando de Almansa Moreno-Barreda
Independent Director5.33yrs€60.00kno data
Marcos Peña Pinto
Adviser1.42yrs€39.00kno data
Fátima García
Independent Director0.83yr€2.00kno data

4.9yrs

Average Tenure

Experienced Board: ROVI's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Laboratorios Farmaceuticos Rovi, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Laboratorios Farmaceuticos Rovi, S.A.
  • Ticker: ROVI
  • Exchange: BME
  • Founded: 1946
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €1.723b
  • Shares outstanding: 55.39m
  • Website: https://www.rovi.es

Number of Employees


Location

  • Laboratorios Farmaceuticos Rovi, S.A.
  • Calle JuliAn Camarillo, 35
  • Madrid
  • Madrid
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ROVIBME (Bolsas y Mercados Espanoles)YesNominative SharesESEURDec 2007
0ILLLSE (London Stock Exchange)YesNominative SharesGBEURDec 2007
41LDB (Deutsche Boerse AG)YesNominative SharesDEEURDec 2007
ROVIEBATS-CHIXE (BATS 'Chi-X Europe')YesNominative SharesGBEURDec 2007
ROVI NBMV (Bolsa Mexicana de Valores)YesNominative SharesMXMXNDec 2007

Biography

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company also d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/25 20:54
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.